SlideShare a Scribd company logo
1 of 77
Urology Department

        post-graduate courses


Benign Prostatic Hyperplasia
          (BPH)
              Presented By
       Prof. Dr. Sherine Ragy
For our Lectures and Scientific resources
visit our web sites,




   Uroainshams.blogspot.com
   Uronotes2012.blogspot.com
                                            ©
Gross Anatomy
• Average Size
 20 gms, depends on age (no correlation between size & symptoms)
• Lobes (Clinically)
  Two lateral lobes (on either side of the supramontanal urethra)
   felt by DRE
  One median lobe (behind the supramontanal urethra)




                                                               ©
Zonal anatomy of the prostate
                    (McNeal classification)
- The transition zone arise and pass beneath the preprostatic
   sphincter to travel on its lateral and posterior sides

-The central zone arise
 circumferentially around
the openings of
the ejaculatory ducts

-The peripheral zone:(70%)

of the prostatic gland.
-anterior fibromuscular stroma




                                                                ©
Zonal anatomy of the prostate
Vascular Supply of prostate
Arterial Supply
• from the inferior vesical artery → prostatic
  artery/arteries → divides into two main branches:
   urethral arteries penetrate the prostatovesical
    junction posterolaterally and approach the bladder
    neck in the 1- to 5-o’clock and 7- to11-o’clock
    positions, (largest branches posteriorly).
   They supply the urethra, the periurethral glands, and
    the transition zone (principal blood supply of the
    adenoma in BPH)
   capsular artery
Venous drainage to periprostatic plexus
                                                            ©
Pathophysiology of BPH
• BPH first develops in the periurethral transition
  zone of the prostate
• BPH is mainly hyperplastic ( increase in the
  number of cells) and not a hypertrophic (increse
  in the size of the cells) process.
• glandular in character
• Small glands demonstrate a predominance of
  fibromuscular stroma



                                                      ©
Pathophysiology of BPH:
• Active smooth muscle tone is regulated by the
  adrenergic nervous system.
• stimulation of the adrenergic nervous system clearly
  results in a dynamic increase in prostatic urethral
  resistance.
• α1A is the most abundant adrenoreceptor subtype in the
  prostate.




    Distribution of α1-adrenergic receptors in the
    lower urinary tract


                                                           ©
Aetiology of BPH- Androgen role
• Development of BPH requires the presence of
  testicular  androgens      during   prostate
  development, puberty and aging.
• Prostate retains ability to respond to androgens
  throughout life via presence of androgen
  receptors (AR). In contrast to decreased AR
  concentration in penis.
•    Prostate maintains high levels of DHT
    throughout life, resulting from the conversion of
    Testosterone to DHT by 5 alpha reductase
    enzymes types 1 and 2.
                                                    ©
©
Natural history of BPH
•    Course of BPH may be highly variable
•    1- to 5-year period, Patients with clinical BPH
     15–50% will have some worsening in symptoms.
     15–55%will have no change,
     15–30% of patients will have symptom improvement.
•    3 to 5 years period:
     60–70% will have some worsening.
     15–25% of patients will show an increase in flow rates,
     15% will have no change,
•    Placebo responses is reported in 20–40% of patients.
                                                                ©
BPH Definitions
• Benign prostatic hyperplasia(BPH):the typical
  histopathologic pattern.

• Bladder outlet obstruction (BOO): functional
  term for any cause of infravesical obstruction.

• Benign prostatic enlargement (BPE):
  prostatic enlargement due to a benign cause, generally
  histologic BPH.

• Benign prostatic obstruction (BPO): this is a
  form of BOO applied when the cause of the outlet
  obstruction is known to be BPE.

                                                           ©
BPH Complications
• Bladder Stones
• Urinary Tract Infections
• Hematuria
• Acute Urinary Retention
• Bladder Decompensation: normal mucosa
  trabeculation  cellules & sacules diverticulae detrusor muscle failure.

• Urinary Incontinence: overflow                incontinence or urge
  incontinence

• Upper Urinary Tract Deterioration and
  Azotemia
                                                                           ©
BPH Diagnosis- History
Medical History
• history of hematuria, UTI, urinary retention
• History of diabetes, nervous system disease (e.g.,
  Parkinson disease or stroke), urethral stricture disease.
• Medications aggravation of symptoms:
  drugs that impair bladder contractility (anticholinergic
   agents)
  Drugs that increase outflow resistance (α-sympatho-
   mimetic agents).


                                                              ©
SYMPTOMS AND SIGNS
The International Prostate Symptom Score (IPSS)
 grade baseline symptom severity,
 assess the response to therapy
 detect symptom progression in those managed by
  watchful waiting.
• AUA S/S Score = Sum Of All 7 Questions
   Mild S/S = Score < 7
   Moderate S/S = Score 8 – 20
   Severe S/S = Score > 20 .


                                                   ©
IPSS
URINARY SYMPTOMS                          Not <         <      half   >      always
(SYMPTOM SCORE CRITERIA)                  at all 1      half   the    half
                                                 time   the    time   the
                                                 in 5   time          time
1. Weak stream
Over the past month, how often have you
had a weak urinary stream?
2. Intermittency
Over the past month, how often have you
found you stopped and started again
several times when you urinate?
3. Sense Incomplete emptying
Over the past month, how often have you
had a sensation of not emptying your
bladder completely after you finished
urinating?
4. Abdominal Straining                    None 1        2      3      4      ≥5
Over the past month, how often have you        time
had to push or strain to begin urination?

                                                                                      ©
IPSS
URINARY SYMPTOMS                            Not <         <      half   >      always
(SYMPTOM SCORE CRITERIA)                    at all 1      half   the    half
                                                   time   the    time   the
                                                   in 5   time          time
2. Frequency
Over the past month, how often have you
had to urinate again less than two hours
after you finished urinating?
4. Urgency
Over the past month, how often have you
found it difficult to postpone urination?

7. Nocturia
Over the past month, how many times
did you most typically get up to urinate
from the time you went to bed at night
until the time you got up in the morning?

 A quality of life score 0-6 is added
                                                                                        ©
SYMPTOMS AND SIGNS
• Storage and Voiding symptoms (assesed by
  IPSS score)
• Retention: Acute retention or Chronic retention
  or acute-on-chronic retention
• Haematuria.
• Uraemic symptoms.




                                                    ©
Examination
Physical Examination
 DRE
 Focused neurologic examination
 (anal sphincter tone, saddle area
 sensation & bulbocavernosus reflex)
 Examination of the external genitalia
 Abdominal examination
Urinalysis.
Serum Creatinine
                                         ©
Serum Prostate-Specific Antigen
             (PSA)
• glycoprotein produced by prostate cells to liquefy semen.
• it is specific to the prostate but not to prostate cancer.
Indication of serum PSA measurement
• Screening asymptomatic men (with DRE)
• Staging of CaP (especially, S.V. & L.N. invasion)
• follow up after R.prostatectomy & radiotherapy.




                                                               ©
Additional Diagnostic investigations
• Further imaging of UUT. if associated hematuria, stone
  diseases, or previous urologic operation.
• Urethrocystogram. If previous urethral instrumentations or
  surgeries.
• Urodynamic and Pressure/flow study. Indicated only in
  complicated cases as cases with previous neurologic disease or
  operation.
• Urethro cystoscopy.
• TRUS & biopsy If elevated PSA
   or Suspicious DRE.


                                                               ©
Sonography of BPH
NON-SURGICAL TREATMENT
Watchful Waiting “Self-Help”
Indicated When:
 • the symptoms are not bothersome,
 • the complications of treatment are greater
   than the inconvenience of the symptoms
 • there is a reluctance to take a daily pill owing
   to side effects and/or the cost of treatment



                                                      ©
MEDICAL THERAPY


 α-adrenergic blockers
 5α-reductase inhibitors
 plant extracts (phytotherapy).
 combinations of these agents.


                                   ©
α-ADRENERGIC BLOCKERS
CLASS OF α-ADRENERGIC BLOCKER   DOSE
Nonselective
Phenoxybenzamine                10 mg bid
Prazosin                        2 mg bid
Alfuzosin IR                    2.5 mg tid
Long-Acting α1
Terazosin                       5 or 10 mg qd
Doxazosin                       4 or 8 mg qd
Alfuzosin SR                    10 mg qd
Subtype Selective
Tamsulosin                      0.4 mg qd
Silodosin                       8 mg qd


                                                ©
α-ADRENERGIC BLOCKERS
Adverse reactions
• asthenia
• dizziness
• first dose phenomenon
• orthostatic hypotension (requiring dose titration) with
   non-subtype-selective blockers
• ejaculatory dysfunction.
• intraoperative floppy iris syndrome(IFIS) described with
   tamsulosin


                                                            ©
5α-reductase inhibitors
• The development of BPH is an androgen-dependent
  process mainly dihydrotestesterone (DHT).
• Testosterone is converted to DHT by the enzyme 5α-
  reductase.




                                                       ©
5α-reductase inhibitors
• 5α-reductase is found in 2 types:
  type 1 : found in the prostate, liver and skin
  type 2 : found in the prostate

• finasteride is competetive inhibitor for type 2
• dutasteride is competitive inhibitor for both types
• maximal prostatic volume suppression is
  achieved after 6 months


                                                    ©
Combination Therapy
Combination Therapy with α-Adrenergic
 Blockers and 5α-Reductase Inhibitors
• combination of dutasteride and tamsulosin was more
  effective than either drug alone, and reduce the
  incidence of acute urinary retention.
• Alpha blocker should be withdrawn from combination
  after the response has been established




                                                       ©
Phytotherapy
•    The pharmacologic use of plants and herbs
     (phytotherapy) for the treatment of LUTS associated
     with BPH is common, e.g. Serenoa Repens, Pygeum
     africanum,etc.
•    The mechanisms of action of are generally unknown
•    Some suggested Mechanisms of Action of Plant
     Extracts
1.   Inhibition of 5α-reductase
2.   Anti-inflammatory
3.   Antiandrogenic,
4.   Inhibition of aromatase
5.   Decrease of sex hormone–binding globulin
6.   Action on α-adrenergic receptors
7.   Free radical scavenger
                                                       ©
Indications of surgical intervention
Absolute indications           Relative indications
• Upper urinary tract          • Moderate symptoms (moderate
  affection.                     IPSS score).

• Uremia.                      • Recurrent UTI.
• Recurrent attacks of acute   • Hematuria.
  retention.                   • Stone bladder.
• Severe obstructive
  symptoms (high IPSS
  score).



                                                        ©
Open prostatectomy
Now rarely used.
Indicated in
• Patients with symptomatic bladder outlet
  obstruction due to BPH and markedly enlarged
  prostate gland,
• Patients with a concomitant bladder condition,
  such as a bladder diverticulum or large bladder
  calculi
• Patients who cannot be placed in the dorsal
  lithotomy position for TURP
Open prostatectomy

Retropubic approach   Suprapubic approach
Minimally Invasive &
  Endoscopic Management of BPH
 Transurethral Resection of the Prostate(TURP)
 Transurethral Needle Ablation of the Prostate(TUNA)
 Transurethral Microwave Therapy(TUMT)
 Lasers
 Transurethral Vaporization of the Prostate
 Transurethral Incision of the Prostate(TUIP)
 Intraprostatic Stents
 PKVP (TUVis) and TURis
                                                    ©
Transurethral Resection of the
           Prostate(TURP)




• TURP is the gold standard for the surgical
  management of BPH.
• All the new therapies are compared to TURP in
  terms of efficacy and side effects.
                                                  ©
Nesbit technique for TURP (1943)
• resection from proximal to distal
  If large middle lobe, start by it first
  1st stage: resect BN (superiorly to inferiorly) 12
   to 3 O’clock
  2nd stage: resect lat. & median lobes (superiorly
   to inferiorly)
  3rd stage: resect apical lobes (inferiorly to
   superiorly )
TURP (Nesbit technique)
     1st stage: resect BN (superiorly to inferiorly)




• Resect BN from 12 to 9 o'clock (until see circular fibers of BN)
2nd stage: resect adenoma in quadrants, (superiorly to inferiorly)
(until see fibers of prostatic capsule)




 (a): Rt lobe (12 to 9 o’clock)
2nd stage: resect adenoma in quadrants, (superiorly to
inferiorly) (until see fibers of prostatic capsule)




 (b): Lt lobe (12 to 3 o’clock)

2nd stage: resect adenoma in quadrants, (superiorly to inferiorly)
(until see fibers of prostatic capsule)




 (c): Floor(9 to 6 o’clock)

3rd stage: Apical adenoma removed immediately proximal to EUS,
preserving veru (inferiorly to superiorly)




 (a): begin next to the veru → toward the 12 o'clock position
3rd stage: Apical adenoma removed immediately proximal to EUS,
preserving veru (inferiorly to superiorly)




 (a): Residual tissue is carefully cleared on the patient's right side
3rd stage: Apical adenoma removed immediately proximal to EUS,
preserving veru (inferiorly to superiorly)




 (c): remaining residual tissue is cleared from the patient's left side
Another technique




• Resection begins at the proximal portion of the middle lobe at the 6-
  o’clock position.
• The resectoscope is placed just proximal to the verumontanum and
  the resection performed always controlling the end point of each cut.
• be aware of the position of the verumontanum to avoid extending
  below this level or otherwise damage to the sphincter mechanism
  may occur.
Another technique (cont.):




• Resection in smaller adenomas is now carried directly to the side
  lobe.
• It depends on the preference of the surgeon whether to begin on
  the left and then to resect the other side or vice versa. .
TURP intra-op complications

• Overall rate is about 3%
   Haemorrhage                       2 -10%
   Hemorrhage needing Transfusion   8%
     Urethral injury                    0 - 2%
     Bladder injury              0 - 2%
     TUR syndrome                       1-7 %
     Extraperitoneal perforation      0.25%
     Recta perforation                < 0.25%
     Mortality                          < 0.2%
Early post-op complications

• Overall rate is about 7-43%
     Urinary retention (Failure to void) 2-8%
     Clot retention                      3-20%
     UTI                                        6-20%
     Epididymo-orchitis                        3-5%
     Septicaemia                               0-5%
     Mortality                                < 0.2%
Late post-op complications

• Overall rate is about 8 %
  –   Bladder neck stenosis              1-3%
  –   Urethral Stricture                  1-2%
  –   Secondary Haemorrhage               1.4%
  –   Incontinence                        1-3%
  –   Retrograde Ejaculation              85 - 100%
  –   Erectile Dysfunction                2 - 13 %
  –   Mortality
       • 30 day post-op                   0.3%
       • 90 day post-op                   1.7%
 • Re-operation rate (within 5 years)   3-8%
TURP in motion
Transurethral radiofrequency needle
   ablation of the prostate (TUNA)

• Low-level radiofrequency is
  transmitted to the prostate
  via a transurethral needle
  delivery system
• The resultant heat causes
  localized necrosis of the
  prostate.
Transurethral radiofrequency needle
       ablation of the prostate (TUNA)

Side-effects
• bleeding in 1/3 of patients
• Short-term urinary retention in 10-40%.
• UTI in 10% and urethral stricture in 2%.
• Irritative urinary symptoms can last for a
  month or more.
• No adverse effects on sexual function
  have been reported.
Transurethral radiofrequency needle
    ablation of the prostate (TUNA)
Efficacy
• TUNA is a successful minimally invasive
  treatment option for symptoms associated
  with prostatic enlargement.
• However, Concerns remain with regard to
  long-term effectiveness.
Transurethral microwave
       thermotherapy (TUMT)
• Microwave energy is delivered
  to    the     prostate    via    an
  intraurethral    catheter     which
  incorporates      a    microwave
  generator        (antenna),       a
  temperature          measurement
  system, and a cooling system to
  prevent damage to the adjacent
  urethra.
Transurethral microwave
      thermotherapy (TUMT)
• The microwave energy produces prostatic
  heating and coagulative necrosis.
• Subsequent shrinkage of the prostate and
  thermal damage to adrenergic neurons (i.e.
  heat-induced adrenergic nerve block) relieves
  obstruction
• Cavities can be demonstrated 3 months post-
  treatment by TRUS.
• Low-energy, high-energy, and high-intensity
  protocols are available.
Transurethral microwave
       thermotherapy (TUMT)
Side effects
• Perineal discomfort is common after TUMT, as is
  urgency, but these symptoms usually resolve in
  a few days.
• Sexual side-effects after TUMT (e.g. impotence,
  retrograde ejaculation) are less frequent that
  after TURP,
• a catheter may be required for 1-2 week
  because of urinary retention in up to 25% of
  patients especially with higher-energy protocols.
HIFU
• A focused ultrasound beam can
  be used to induce a rise in
  temperature in the prostate, or
  indeed in any other tissue to
  which it is applied.
• A transrectal probe is used for
  HIFU treatment of the prostate
• There are no randomized trials
  comparing       its  effectiveness
  against       other      treatment
  modalities.
TUVP

• This technique vaporizes     and
  dessicates the prostate.
Advantages
• TUVP is as effective as TURP for
  symptom control and relief of
  bladder outlet obstruction.
• Requirement for blood transfusion
  may be slightly less after TUVP
  than after TURP.
•
TUVP

Side effects
• Retrograde ejaculation occurs 70-100% of
  patients and impotence in 0-15%.
• Irritative symptoms seem to be more
  troublesome than after TURP and can last
  for 4-6 weeks.
• TUVP does not provide tissue for
  histological examination, and so prostate
  cancers cannot be detected.
LASER
• Light
• Amplification
 by the
• Stimulated
• Emission of
• Radiation
LASER
• Penetration depends
  on wavelength.
• Shorter wavelengths
  (600nm-700nm)        are
  absorbed within a couple
  of mm by hemoglobin.
• Longer wavelengths
  (1,000nm + ) are
  absorbed   by   fat   and
  water.
Laser Therapy
Mechanism of action of Laser in prostatectomy:
• Ablation (coagulation necrosis).
• Resection.
• Vaporization.
These mechanisms are employed through
1)   Visual laser ablation of the prostate.
2)   Laser vaporization of the prostate.
3)   Laser resection of the prostate.
4)   Laser enucleation of the prostate (with tissue morcellation).
5)   Laser incision of the prostate.
6)   Interstitial laser coagulation of the prostate.
Laser delivery system
Laser Therapy
There are four types of laser for the prostate:
1) Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG)
   laser: utilizes wavelengths of 1064 nm causing
   coagulative necrosis of the prostate.
2) Potassium Titanyl Phosphate (KTP) laser:
  Doubling the frequency of pulsed (Nd:YAG) laser energy with a KTP
   crystal has led to the creation of a 532 nm wavelength selectively
   absorbed by Hb.
  The 60-W KTP laser has proved that a higher-power laser beam could
   speed up vaporization.
  So, the 80-W KTP laser was introduced (Green light photoselective
    vaporization laser system).
Laser Therapy
3) Holmium: Yttrium-Aluminum-Garnet (Ho:YAG) laser:
 •   The Ho:YAG utilises wavelength of 2140 nm.
 •   It causes vaporization rather than coagulation.
 •   can be used for resection (HoLRP) or enucleation
     (HoLEP).
4) Diode laser:
  has 3 components:
 1. portable diode laser unit,
 2. specialized fiber optic delivery system that allows optical
    monitoring of tissue temperatures,
 3. laser.
Visual laser ablation of the
                 prostate
It is based on the principle of laser coagulation.
Surgical technique:
 The laser energy is delivered to the prostate gland with a side-firing,
  noncontact, free-beam laser.
 The most widely used laser energy is the Nd:YAG.
 The obstructive tissue then starts to slough during the next 4 to 8
  postoperative weeks, leading to a patent prostatic urethra.
Adverse effects:
 Prolonged irritative voiding
 symptoms which may last for
 weeks and sometimes months.
Laser vaporization of the prostate
 The Green Light company improved the power of the 532
  nm laser up to 80 W KTP and 120 W high-performance
  system (HPS) with lithium triborate (LBO).
 Photoselective vaporization of the prostate (PVP) is
  considered an easy technique creating prostatic fossa
  resembling TURP.
 Indications of PVP:
 1) Prostates larger than 80 ml can be done.
 2) Patients with a high risk.
 3) Elderly aged 80 years or more.
 4) Anticoagulant users .
Laser vaporization of the
                prostate
Surgical technique:
 Vaporization is started at the 6 o'clock position or at one
  of the two lateral lobes of the prostate.
 Effective lasing makes many air bubbles.
 A Foley catheter is placed for less than 24 hours before a
  voiding trial is done.
Advantages
  No significant blood loss or fluid absorption was noted
  during or immediately after PVP.
Side effects transient hematuria (8.6%), dysuria (9.3%)
  and urinary retention (5%).
Laser resection of the prostate

It is based on the principle of laser vaporization.
Holmium: YAG is the most widely used laser for this
  technique.


Surgical technique
the laser fiber cuts the prostatic lobes into pieces small
  enough to be evacuated through the resectoscope
  sheath to create a TUR-like cavity.
Laser enucleation of the prostate
               (with tissue morcellation)

Indication:
   Alternative to open prostatectomy in large prostates.
Surgical technique
 Bilateral bladder neck incisions from orifices to veru.
 The median lobe is enucleated then the lateral lobes.
 Prostate tissues in the bladder are fragmented and
  aspirated with the morcellator.
Adverse effects:
  Recatheterization (2.9%), UTI (2.3%), urethral stricture or
  bladder-neck contracture (3.2%) and reoperation (2.8%).
Laser incision of the prostate

• based on the principle of tissue vaporization
• a contact-tip laser fiber is used to deliver high
  energy along the prostatic urethra, causing a linear
  tract of tissue vaporization.
• It is performed on relatively small glands (< 30 g).
INTERSTITIAL LASER COAGULATION

  A standard cystoscope is used to insert
   the laser fiber transurethrally into the
   prostate gland.
  The intraprostatic temperature reaches
   100°C within a few seconds and is
   maintained for150 seconds resulting in
   tissue coagulation.
 Adverse Effects
 Retreatment rate in 16% and UTI in 20%
  of patients.
Plasmakinetic vaporesection of the
         prostate (PKVP)




A new technique based on creating a
plasma arc, vaporizing tissue and achieving
hemostasis to a predictable depth.
Plasmakinetic vaporesection of the
            prostate (PKVP)




• current is passed through the active electrode of the
  device that approaches boiling point and a plasma
  corona is formed, creating very high resistance between
  the active and return electrodes.
• Tissue entering the corona (lower resistance) is
  vaporized and adjacent tissue is sealed up to 0.5 mm.
Plasmakinetic vaporesection of the
           prostate (PKVP)
   Advantages of PKVP
1) The bipolar current and the use of saline irrigation
   eliminates the risk of TUR syndrome.
2) Hemostasis is achieved to a predictable depth.
3) The working element is the return electrode , thus,
   eliminating the risk of skin burns and obturator jerk.
4) Safe to be used in patients with cardiac pacemakers.
5) used in high risk patients, patients with bleeding disorder
   and patients receiving anticoagulative therapy.
  Disadvantages of PKVP
    It does not provide histopathological specimens which
  may miss incidental cancers.
Trans-urethral resection in saline
             (TURis)
• Using a bipolar electrode this technique
 allows working with saline medium.
• The technique offers familial technique
 with minimal bleeding and use in high risk
 patients with cardiac pacemakers and
 arrhythmias.
TURis and TUVis (PKVP) in motion
Thank You

More Related Content

What's hot

Benign & Malignant Diseases Of The Prostate
Benign &  Malignant  Diseases  Of  The  Prostate Benign &  Malignant  Diseases  Of  The  Prostate
Benign & Malignant Diseases Of The Prostate Sodo
 
BPH- Pathology & Investigations
BPH- Pathology & InvestigationsBPH- Pathology & Investigations
BPH- Pathology & InvestigationsAnkur Agarwal
 
Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)Abdullah Mohammad
 
Prostate Biopsy (PBx).pptx
Prostate Biopsy (PBx).pptxProstate Biopsy (PBx).pptx
Prostate Biopsy (PBx).pptxRabindra Tamang
 
Carcinoma of the prostate
Carcinoma of the prostateCarcinoma of the prostate
Carcinoma of the prostateOsman Altohamy
 
Hematuria - evaluation and management
Hematuria - evaluation and managementHematuria - evaluation and management
Hematuria - evaluation and managementGovtRoyapettahHospit
 
Medical management of bph
Medical management of bphMedical management of bph
Medical management of bphbbthapa
 
Etiology and pathophysiology of bph
Etiology and pathophysiology of bphEtiology and pathophysiology of bph
Etiology and pathophysiology of bphAhmed Eliwa
 
Benign prostatic hyperplasia (bph)
Benign prostatic hyperplasia (bph)Benign prostatic hyperplasia (bph)
Benign prostatic hyperplasia (bph)Makafui Yigah
 
Benign Prostatic Hyperplasia
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia
Benign Prostatic HyperplasiaMonitoshPaul
 
BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...
BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...
BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...Gagan Adhikari
 
Benign prostatic hyperplasia by Sayed Eleweedy
Benign prostatic hyperplasia by Sayed EleweedyBenign prostatic hyperplasia by Sayed Eleweedy
Benign prostatic hyperplasia by Sayed EleweedySayed Eleweedy
 
Benign Prostate Hypertrophy
Benign Prostate HypertrophyBenign Prostate Hypertrophy
Benign Prostate HypertrophyRutviPatel25
 

What's hot (20)

Benign & Malignant Diseases Of The Prostate
Benign &  Malignant  Diseases  Of  The  Prostate Benign &  Malignant  Diseases  Of  The  Prostate
Benign & Malignant Diseases Of The Prostate
 
BPH- Pathology & Investigations
BPH- Pathology & InvestigationsBPH- Pathology & Investigations
BPH- Pathology & Investigations
 
Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)Benign Prostatic Hyperplasia (BPH and LUTS)
Benign Prostatic Hyperplasia (BPH and LUTS)
 
Bph dr mnr
Bph dr mnrBph dr mnr
Bph dr mnr
 
Prostate Biopsy (PBx).pptx
Prostate Biopsy (PBx).pptxProstate Biopsy (PBx).pptx
Prostate Biopsy (PBx).pptx
 
Carcinoma of the prostate
Carcinoma of the prostateCarcinoma of the prostate
Carcinoma of the prostate
 
Bph
BphBph
Bph
 
Prostate Cancer (Urology)
Prostate Cancer (Urology)Prostate Cancer (Urology)
Prostate Cancer (Urology)
 
Hematuria - evaluation and management
Hematuria - evaluation and managementHematuria - evaluation and management
Hematuria - evaluation and management
 
Medical management of bph
Medical management of bphMedical management of bph
Medical management of bph
 
Etiology and pathophysiology of bph
Etiology and pathophysiology of bphEtiology and pathophysiology of bph
Etiology and pathophysiology of bph
 
Benign prostatic hyperplasia (bph)
Benign prostatic hyperplasia (bph)Benign prostatic hyperplasia (bph)
Benign prostatic hyperplasia (bph)
 
Prostate BPH- pathophysiology
Prostate  BPH- pathophysiologyProstate  BPH- pathophysiology
Prostate BPH- pathophysiology
 
Benign Prostatic Hyperplasia
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
 
BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...
BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...
BENIGN PROSTATIC HYPERPLASIA: Epidemiology, Etiology, Pathophysiology, and ev...
 
Overactive bladder
Overactive bladderOveractive bladder
Overactive bladder
 
Benign Prostatic Hyperplasia
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
 
Benign prostatic hyperplasia by Sayed Eleweedy
Benign prostatic hyperplasia by Sayed EleweedyBenign prostatic hyperplasia by Sayed Eleweedy
Benign prostatic hyperplasia by Sayed Eleweedy
 
Benign Prostate Hypertrophy
Benign Prostate HypertrophyBenign Prostate Hypertrophy
Benign Prostate Hypertrophy
 
Prostatitis
ProstatitisProstatitis
Prostatitis
 

Similar to BPH

BPH & its management by Dr Nesar
BPH & its management by Dr NesarBPH & its management by Dr Nesar
BPH & its management by Dr NesarStudent
 
Bladder outflow obstruction.ppt
Bladder outflow obstruction.pptBladder outflow obstruction.ppt
Bladder outflow obstruction.ppthskhan27
 
Benign Prostate Hyperplasia
Benign Prostate HyperplasiaBenign Prostate Hyperplasia
Benign Prostate HyperplasiaSaba Khan
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasiafikri asyura
 
prostate disease CASE DISCUSSION
prostate disease CASE DISCUSSIONprostate disease CASE DISCUSSION
prostate disease CASE DISCUSSIONPARUL UNIVERSITY
 
Prostate Benign Prostatic Hyperplasia(BPH)- overview
Prostate  Benign Prostatic Hyperplasia(BPH)- overviewProstate  Benign Prostatic Hyperplasia(BPH)- overview
Prostate Benign Prostatic Hyperplasia(BPH)- overviewGovtRoyapettahHospit
 
Benign enlargement of prostate
Benign enlargement of prostateBenign enlargement of prostate
Benign enlargement of prostatesunil kumar daha
 
DISEASES OF PROSTATE.pptx
DISEASES OF PROSTATE.pptxDISEASES OF PROSTATE.pptx
DISEASES OF PROSTATE.pptxSumantra Dey
 
14. Benign prostatic hyperplasia.pptx
14. Benign prostatic hyperplasia.pptx14. Benign prostatic hyperplasia.pptx
14. Benign prostatic hyperplasia.pptxSani42793
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasiaSandeep Patil
 
Lower Urinary Tract Symptoms(LUTS).pptx
Lower Urinary Tract Symptoms(LUTS).pptxLower Urinary Tract Symptoms(LUTS).pptx
Lower Urinary Tract Symptoms(LUTS).pptxDrMohaiminurRahmanMS
 

Similar to BPH (20)

BPH & its management by Dr Nesar
BPH & its management by Dr NesarBPH & its management by Dr Nesar
BPH & its management by Dr Nesar
 
Bph 4th yr
Bph 4th yrBph 4th yr
Bph 4th yr
 
Bph..ibrahim hakami
Bph..ibrahim hakamiBph..ibrahim hakami
Bph..ibrahim hakami
 
BPH-medical management
BPH-medical managementBPH-medical management
BPH-medical management
 
Bladder outflow obstruction.ppt
Bladder outflow obstruction.pptBladder outflow obstruction.ppt
Bladder outflow obstruction.ppt
 
Principles of management,bph
Principles of management,bphPrinciples of management,bph
Principles of management,bph
 
Benign Prostate Hyperplasia
Benign Prostate HyperplasiaBenign Prostate Hyperplasia
Benign Prostate Hyperplasia
 
Urology 5th year, 1st lecture (Dr. Sarwar)
Urology 5th year, 1st lecture (Dr. Sarwar)Urology 5th year, 1st lecture (Dr. Sarwar)
Urology 5th year, 1st lecture (Dr. Sarwar)
 
Benign Prostate Hyperplasia
Benign Prostate HyperplasiaBenign Prostate Hyperplasia
Benign Prostate Hyperplasia
 
Benign Prostate Hyperplasia (BPH)
Benign Prostate Hyperplasia (BPH)Benign Prostate Hyperplasia (BPH)
Benign Prostate Hyperplasia (BPH)
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasia
 
prostate disease CASE DISCUSSION
prostate disease CASE DISCUSSIONprostate disease CASE DISCUSSION
prostate disease CASE DISCUSSION
 
Prostate Benign Prostatic Hyperplasia(BPH)- overview
Prostate  Benign Prostatic Hyperplasia(BPH)- overviewProstate  Benign Prostatic Hyperplasia(BPH)- overview
Prostate Benign Prostatic Hyperplasia(BPH)- overview
 
Benign enlargement of prostate
Benign enlargement of prostateBenign enlargement of prostate
Benign enlargement of prostate
 
DISEASES OF PROSTATE.pptx
DISEASES OF PROSTATE.pptxDISEASES OF PROSTATE.pptx
DISEASES OF PROSTATE.pptx
 
Hepatoma.pptx
Hepatoma.pptxHepatoma.pptx
Hepatoma.pptx
 
Prostate diseases
Prostate diseasesProstate diseases
Prostate diseases
 
14. Benign prostatic hyperplasia.pptx
14. Benign prostatic hyperplasia.pptx14. Benign prostatic hyperplasia.pptx
14. Benign prostatic hyperplasia.pptx
 
Benign prostatic hyperplasia
Benign prostatic hyperplasiaBenign prostatic hyperplasia
Benign prostatic hyperplasia
 
Lower Urinary Tract Symptoms(LUTS).pptx
Lower Urinary Tract Symptoms(LUTS).pptxLower Urinary Tract Symptoms(LUTS).pptx
Lower Urinary Tract Symptoms(LUTS).pptx
 

More from Mohammed Abd El Wadood

Critical appraisal: How to read a scientific paper?
Critical appraisal: How to read a scientific paper?Critical appraisal: How to read a scientific paper?
Critical appraisal: How to read a scientific paper?Mohammed Abd El Wadood
 
How to make a personal plan that really works: Practical approach
How to make a personal plan that really works: Practical approachHow to make a personal plan that really works: Practical approach
How to make a personal plan that really works: Practical approachMohammed Abd El Wadood
 
Voiding dysfunction A Simple Approach Towards Understanding and Management - ...
Voiding dysfunction A Simple Approach Towards Understanding and Management - ...Voiding dysfunction A Simple Approach Towards Understanding and Management - ...
Voiding dysfunction A Simple Approach Towards Understanding and Management - ...Mohammed Abd El Wadood
 
Imaging in urology: part 2 other conventional imaging
Imaging in urology: part 2  other conventional imagingImaging in urology: part 2  other conventional imaging
Imaging in urology: part 2 other conventional imagingMohammed Abd El Wadood
 
Hypospadias 3: MAGPI & snod grass (TIP) step by step operative urology series
Hypospadias 3: MAGPI & snod grass (TIP)   step by step operative urology series Hypospadias 3: MAGPI & snod grass (TIP)   step by step operative urology series
Hypospadias 3: MAGPI & snod grass (TIP) step by step operative urology series Mohammed Abd El Wadood
 
Hypospadias 2 orthoplasty & ttt options step by step oper series
Hypospadias 2 orthoplasty & ttt options   step by step oper series Hypospadias 2 orthoplasty & ttt options   step by step oper series
Hypospadias 2 orthoplasty & ttt options step by step oper series Mohammed Abd El Wadood
 
Hypospadias part 1 introd (step by step oper series)
Hypospadias part 1 introd   (step by step oper series) Hypospadias part 1 introd   (step by step oper series)
Hypospadias part 1 introd (step by step oper series) Mohammed Abd El Wadood
 
Targeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinomaTargeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinomaMohammed Abd El Wadood
 
Urodynamic studies for neurogenic bladder
Urodynamic studies for neurogenic bladderUrodynamic studies for neurogenic bladder
Urodynamic studies for neurogenic bladderMohammed Abd El Wadood
 
Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...
Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...
Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...Mohammed Abd El Wadood
 
Evaluation of sexual function after prostatectomy- SHIM score
Evaluation of sexual function after prostatectomy- SHIM scoreEvaluation of sexual function after prostatectomy- SHIM score
Evaluation of sexual function after prostatectomy- SHIM scoreMohammed Abd El Wadood
 
Augmented anastomotic repair sing dorsal oral mucosal graft
Augmented anastomotic repair  sing dorsal oral mucosal graftAugmented anastomotic repair  sing dorsal oral mucosal graft
Augmented anastomotic repair sing dorsal oral mucosal graftMohammed Abd El Wadood
 
One stage urethroplasty of penile urethra using penile skin flap
One stage urethroplasty of penile urethra using penile skin flapOne stage urethroplasty of penile urethra using penile skin flap
One stage urethroplasty of penile urethra using penile skin flapMohammed Abd El Wadood
 
Two stage urethroplasty of bulbar urethra
Two stage urethroplasty of bulbar urethraTwo stage urethroplasty of bulbar urethra
Two stage urethroplasty of bulbar urethraMohammed Abd El Wadood
 

More from Mohammed Abd El Wadood (20)

Critical appraisal: How to read a scientific paper?
Critical appraisal: How to read a scientific paper?Critical appraisal: How to read a scientific paper?
Critical appraisal: How to read a scientific paper?
 
How to make a personal plan that really works: Practical approach
How to make a personal plan that really works: Practical approachHow to make a personal plan that really works: Practical approach
How to make a personal plan that really works: Practical approach
 
Voiding dysfunction A Simple Approach Towards Understanding and Management - ...
Voiding dysfunction A Simple Approach Towards Understanding and Management - ...Voiding dysfunction A Simple Approach Towards Understanding and Management - ...
Voiding dysfunction A Simple Approach Towards Understanding and Management - ...
 
TURP step by step operative urology
TURP step by step operative urologyTURP step by step operative urology
TURP step by step operative urology
 
Hematuria for undergraduates
Hematuria for undergraduatesHematuria for undergraduates
Hematuria for undergraduates
 
Inguino-scrotal lumps
Inguino-scrotal lumpsInguino-scrotal lumps
Inguino-scrotal lumps
 
Imaging in urology: part 2 other conventional imaging
Imaging in urology: part 2  other conventional imagingImaging in urology: part 2  other conventional imaging
Imaging in urology: part 2 other conventional imaging
 
Imaging in urology: part 1 kub & ivp
Imaging in urology: part 1  kub & ivpImaging in urology: part 1  kub & ivp
Imaging in urology: part 1 kub & ivp
 
Hypospadias 3: MAGPI & snod grass (TIP) step by step operative urology series
Hypospadias 3: MAGPI & snod grass (TIP)   step by step operative urology series Hypospadias 3: MAGPI & snod grass (TIP)   step by step operative urology series
Hypospadias 3: MAGPI & snod grass (TIP) step by step operative urology series
 
Hypospadias 2 orthoplasty & ttt options step by step oper series
Hypospadias 2 orthoplasty & ttt options   step by step oper series Hypospadias 2 orthoplasty & ttt options   step by step oper series
Hypospadias 2 orthoplasty & ttt options step by step oper series
 
Hypospadias part 1 introd (step by step oper series)
Hypospadias part 1 introd   (step by step oper series) Hypospadias part 1 introd   (step by step oper series)
Hypospadias part 1 introd (step by step oper series)
 
Targeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinomaTargeted therapy for metastatic renal cell carcinoma
Targeted therapy for metastatic renal cell carcinoma
 
Urodynamic studies for neurogenic bladder
Urodynamic studies for neurogenic bladderUrodynamic studies for neurogenic bladder
Urodynamic studies for neurogenic bladder
 
Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...
Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...
Hypospadias 2 new techniques: longitudinal preputial flap & single-stage dors...
 
Metastatic casteration resistant caP
Metastatic casteration resistant caPMetastatic casteration resistant caP
Metastatic casteration resistant caP
 
Evaluation of sexual function after prostatectomy- SHIM score
Evaluation of sexual function after prostatectomy- SHIM scoreEvaluation of sexual function after prostatectomy- SHIM score
Evaluation of sexual function after prostatectomy- SHIM score
 
Recurrent UTI in females
Recurrent UTI in femalesRecurrent UTI in females
Recurrent UTI in females
 
Augmented anastomotic repair sing dorsal oral mucosal graft
Augmented anastomotic repair  sing dorsal oral mucosal graftAugmented anastomotic repair  sing dorsal oral mucosal graft
Augmented anastomotic repair sing dorsal oral mucosal graft
 
One stage urethroplasty of penile urethra using penile skin flap
One stage urethroplasty of penile urethra using penile skin flapOne stage urethroplasty of penile urethra using penile skin flap
One stage urethroplasty of penile urethra using penile skin flap
 
Two stage urethroplasty of bulbar urethra
Two stage urethroplasty of bulbar urethraTwo stage urethroplasty of bulbar urethra
Two stage urethroplasty of bulbar urethra
 

Recently uploaded

Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxEx WHO/USAID
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxAbhishek943418
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinethanaram patel
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSapna Thakur
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfDivya Kanojiya
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 

Recently uploaded (20)

Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-JANGAMA VISHA .pptx-
JANGAMA VISHA .pptx-
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
World-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptxWorld-Health-Day-2024-My-Health-My-Right.pptx
World-Health-Day-2024-My-Health-My-Right.pptx
 
SHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptxSHOCK (Medical SURGICAL BASED EDITION)).pptx
SHOCK (Medical SURGICAL BASED EDITION)).pptx
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicine
 
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna ThakurSCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
SCHOOL HEALTH SERVICES.pptx made by Sapna Thakur
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Role of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdfRole of medicinal and aromatic plants in national economy PDF.pdf
Role of medicinal and aromatic plants in national economy PDF.pdf
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 

BPH

  • 1. Urology Department post-graduate courses Benign Prostatic Hyperplasia (BPH) Presented By Prof. Dr. Sherine Ragy
  • 2. For our Lectures and Scientific resources visit our web sites, Uroainshams.blogspot.com Uronotes2012.blogspot.com ©
  • 3. Gross Anatomy • Average Size 20 gms, depends on age (no correlation between size & symptoms) • Lobes (Clinically)  Two lateral lobes (on either side of the supramontanal urethra) felt by DRE  One median lobe (behind the supramontanal urethra) ©
  • 4. Zonal anatomy of the prostate (McNeal classification) - The transition zone arise and pass beneath the preprostatic sphincter to travel on its lateral and posterior sides -The central zone arise circumferentially around the openings of the ejaculatory ducts -The peripheral zone:(70%) of the prostatic gland. -anterior fibromuscular stroma ©
  • 5. Zonal anatomy of the prostate
  • 6. Vascular Supply of prostate Arterial Supply • from the inferior vesical artery → prostatic artery/arteries → divides into two main branches:  urethral arteries penetrate the prostatovesical junction posterolaterally and approach the bladder neck in the 1- to 5-o’clock and 7- to11-o’clock positions, (largest branches posteriorly).  They supply the urethra, the periurethral glands, and the transition zone (principal blood supply of the adenoma in BPH)  capsular artery Venous drainage to periprostatic plexus ©
  • 7. Pathophysiology of BPH • BPH first develops in the periurethral transition zone of the prostate • BPH is mainly hyperplastic ( increase in the number of cells) and not a hypertrophic (increse in the size of the cells) process. • glandular in character • Small glands demonstrate a predominance of fibromuscular stroma ©
  • 8. Pathophysiology of BPH: • Active smooth muscle tone is regulated by the adrenergic nervous system. • stimulation of the adrenergic nervous system clearly results in a dynamic increase in prostatic urethral resistance. • α1A is the most abundant adrenoreceptor subtype in the prostate. Distribution of α1-adrenergic receptors in the lower urinary tract ©
  • 9. Aetiology of BPH- Androgen role • Development of BPH requires the presence of testicular androgens during prostate development, puberty and aging. • Prostate retains ability to respond to androgens throughout life via presence of androgen receptors (AR). In contrast to decreased AR concentration in penis. • Prostate maintains high levels of DHT throughout life, resulting from the conversion of Testosterone to DHT by 5 alpha reductase enzymes types 1 and 2. ©
  • 10. ©
  • 11. Natural history of BPH • Course of BPH may be highly variable • 1- to 5-year period, Patients with clinical BPH  15–50% will have some worsening in symptoms.  15–55%will have no change,  15–30% of patients will have symptom improvement. • 3 to 5 years period:  60–70% will have some worsening.  15–25% of patients will show an increase in flow rates,  15% will have no change, • Placebo responses is reported in 20–40% of patients. ©
  • 12. BPH Definitions • Benign prostatic hyperplasia(BPH):the typical histopathologic pattern. • Bladder outlet obstruction (BOO): functional term for any cause of infravesical obstruction. • Benign prostatic enlargement (BPE): prostatic enlargement due to a benign cause, generally histologic BPH. • Benign prostatic obstruction (BPO): this is a form of BOO applied when the cause of the outlet obstruction is known to be BPE. ©
  • 13. BPH Complications • Bladder Stones • Urinary Tract Infections • Hematuria • Acute Urinary Retention • Bladder Decompensation: normal mucosa trabeculation  cellules & sacules diverticulae detrusor muscle failure. • Urinary Incontinence: overflow incontinence or urge incontinence • Upper Urinary Tract Deterioration and Azotemia ©
  • 14. BPH Diagnosis- History Medical History • history of hematuria, UTI, urinary retention • History of diabetes, nervous system disease (e.g., Parkinson disease or stroke), urethral stricture disease. • Medications aggravation of symptoms:  drugs that impair bladder contractility (anticholinergic agents)  Drugs that increase outflow resistance (α-sympatho- mimetic agents). ©
  • 15. SYMPTOMS AND SIGNS The International Prostate Symptom Score (IPSS)  grade baseline symptom severity,  assess the response to therapy  detect symptom progression in those managed by watchful waiting. • AUA S/S Score = Sum Of All 7 Questions  Mild S/S = Score < 7  Moderate S/S = Score 8 – 20  Severe S/S = Score > 20 . ©
  • 16. IPSS URINARY SYMPTOMS Not < < half > always (SYMPTOM SCORE CRITERIA) at all 1 half the half time the time the in 5 time time 1. Weak stream Over the past month, how often have you had a weak urinary stream? 2. Intermittency Over the past month, how often have you found you stopped and started again several times when you urinate? 3. Sense Incomplete emptying Over the past month, how often have you had a sensation of not emptying your bladder completely after you finished urinating? 4. Abdominal Straining None 1 2 3 4 ≥5 Over the past month, how often have you time had to push or strain to begin urination? ©
  • 17. IPSS URINARY SYMPTOMS Not < < half > always (SYMPTOM SCORE CRITERIA) at all 1 half the half time the time the in 5 time time 2. Frequency Over the past month, how often have you had to urinate again less than two hours after you finished urinating? 4. Urgency Over the past month, how often have you found it difficult to postpone urination? 7. Nocturia Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning? A quality of life score 0-6 is added ©
  • 18. SYMPTOMS AND SIGNS • Storage and Voiding symptoms (assesed by IPSS score) • Retention: Acute retention or Chronic retention or acute-on-chronic retention • Haematuria. • Uraemic symptoms. ©
  • 19. Examination Physical Examination DRE Focused neurologic examination (anal sphincter tone, saddle area sensation & bulbocavernosus reflex) Examination of the external genitalia Abdominal examination Urinalysis. Serum Creatinine ©
  • 20. Serum Prostate-Specific Antigen (PSA) • glycoprotein produced by prostate cells to liquefy semen. • it is specific to the prostate but not to prostate cancer. Indication of serum PSA measurement • Screening asymptomatic men (with DRE) • Staging of CaP (especially, S.V. & L.N. invasion) • follow up after R.prostatectomy & radiotherapy. ©
  • 21. Additional Diagnostic investigations • Further imaging of UUT. if associated hematuria, stone diseases, or previous urologic operation. • Urethrocystogram. If previous urethral instrumentations or surgeries. • Urodynamic and Pressure/flow study. Indicated only in complicated cases as cases with previous neurologic disease or operation. • Urethro cystoscopy. • TRUS & biopsy If elevated PSA or Suspicious DRE. ©
  • 23. NON-SURGICAL TREATMENT Watchful Waiting “Self-Help” Indicated When: • the symptoms are not bothersome, • the complications of treatment are greater than the inconvenience of the symptoms • there is a reluctance to take a daily pill owing to side effects and/or the cost of treatment ©
  • 24. MEDICAL THERAPY  α-adrenergic blockers  5α-reductase inhibitors  plant extracts (phytotherapy).  combinations of these agents. ©
  • 25. α-ADRENERGIC BLOCKERS CLASS OF α-ADRENERGIC BLOCKER DOSE Nonselective Phenoxybenzamine 10 mg bid Prazosin 2 mg bid Alfuzosin IR 2.5 mg tid Long-Acting α1 Terazosin 5 or 10 mg qd Doxazosin 4 or 8 mg qd Alfuzosin SR 10 mg qd Subtype Selective Tamsulosin 0.4 mg qd Silodosin 8 mg qd ©
  • 26. α-ADRENERGIC BLOCKERS Adverse reactions • asthenia • dizziness • first dose phenomenon • orthostatic hypotension (requiring dose titration) with non-subtype-selective blockers • ejaculatory dysfunction. • intraoperative floppy iris syndrome(IFIS) described with tamsulosin ©
  • 27. 5α-reductase inhibitors • The development of BPH is an androgen-dependent process mainly dihydrotestesterone (DHT). • Testosterone is converted to DHT by the enzyme 5α- reductase. ©
  • 28. 5α-reductase inhibitors • 5α-reductase is found in 2 types: type 1 : found in the prostate, liver and skin type 2 : found in the prostate • finasteride is competetive inhibitor for type 2 • dutasteride is competitive inhibitor for both types • maximal prostatic volume suppression is achieved after 6 months ©
  • 29. Combination Therapy Combination Therapy with α-Adrenergic Blockers and 5α-Reductase Inhibitors • combination of dutasteride and tamsulosin was more effective than either drug alone, and reduce the incidence of acute urinary retention. • Alpha blocker should be withdrawn from combination after the response has been established ©
  • 30. Phytotherapy • The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common, e.g. Serenoa Repens, Pygeum africanum,etc. • The mechanisms of action of are generally unknown • Some suggested Mechanisms of Action of Plant Extracts 1. Inhibition of 5α-reductase 2. Anti-inflammatory 3. Antiandrogenic, 4. Inhibition of aromatase 5. Decrease of sex hormone–binding globulin 6. Action on α-adrenergic receptors 7. Free radical scavenger ©
  • 31. Indications of surgical intervention Absolute indications Relative indications • Upper urinary tract • Moderate symptoms (moderate affection. IPSS score). • Uremia. • Recurrent UTI. • Recurrent attacks of acute • Hematuria. retention. • Stone bladder. • Severe obstructive symptoms (high IPSS score). ©
  • 32. Open prostatectomy Now rarely used. Indicated in • Patients with symptomatic bladder outlet obstruction due to BPH and markedly enlarged prostate gland, • Patients with a concomitant bladder condition, such as a bladder diverticulum or large bladder calculi • Patients who cannot be placed in the dorsal lithotomy position for TURP
  • 34. Minimally Invasive & Endoscopic Management of BPH  Transurethral Resection of the Prostate(TURP)  Transurethral Needle Ablation of the Prostate(TUNA)  Transurethral Microwave Therapy(TUMT)  Lasers  Transurethral Vaporization of the Prostate  Transurethral Incision of the Prostate(TUIP)  Intraprostatic Stents  PKVP (TUVis) and TURis ©
  • 35. Transurethral Resection of the Prostate(TURP) • TURP is the gold standard for the surgical management of BPH. • All the new therapies are compared to TURP in terms of efficacy and side effects. ©
  • 36. Nesbit technique for TURP (1943) • resection from proximal to distal  If large middle lobe, start by it first  1st stage: resect BN (superiorly to inferiorly) 12 to 3 O’clock  2nd stage: resect lat. & median lobes (superiorly to inferiorly)  3rd stage: resect apical lobes (inferiorly to superiorly )
  • 37. TURP (Nesbit technique) 1st stage: resect BN (superiorly to inferiorly) • Resect BN from 12 to 9 o'clock (until see circular fibers of BN)
  • 38. 2nd stage: resect adenoma in quadrants, (superiorly to inferiorly) (until see fibers of prostatic capsule)  (a): Rt lobe (12 to 9 o’clock)
  • 39. 2nd stage: resect adenoma in quadrants, (superiorly to inferiorly) (until see fibers of prostatic capsule)  (b): Lt lobe (12 to 3 o’clock) 
  • 40. 2nd stage: resect adenoma in quadrants, (superiorly to inferiorly) (until see fibers of prostatic capsule)  (c): Floor(9 to 6 o’clock) 
  • 41. 3rd stage: Apical adenoma removed immediately proximal to EUS, preserving veru (inferiorly to superiorly)  (a): begin next to the veru → toward the 12 o'clock position
  • 42. 3rd stage: Apical adenoma removed immediately proximal to EUS, preserving veru (inferiorly to superiorly)  (a): Residual tissue is carefully cleared on the patient's right side
  • 43. 3rd stage: Apical adenoma removed immediately proximal to EUS, preserving veru (inferiorly to superiorly)  (c): remaining residual tissue is cleared from the patient's left side
  • 44. Another technique • Resection begins at the proximal portion of the middle lobe at the 6- o’clock position. • The resectoscope is placed just proximal to the verumontanum and the resection performed always controlling the end point of each cut. • be aware of the position of the verumontanum to avoid extending below this level or otherwise damage to the sphincter mechanism may occur.
  • 45. Another technique (cont.): • Resection in smaller adenomas is now carried directly to the side lobe. • It depends on the preference of the surgeon whether to begin on the left and then to resect the other side or vice versa. .
  • 46. TURP intra-op complications • Overall rate is about 3%  Haemorrhage 2 -10%  Hemorrhage needing Transfusion 8%  Urethral injury 0 - 2%  Bladder injury 0 - 2%  TUR syndrome 1-7 %  Extraperitoneal perforation 0.25%  Recta perforation < 0.25%  Mortality < 0.2%
  • 47. Early post-op complications • Overall rate is about 7-43%  Urinary retention (Failure to void) 2-8%  Clot retention 3-20%  UTI 6-20%  Epididymo-orchitis 3-5%  Septicaemia 0-5%  Mortality < 0.2%
  • 48. Late post-op complications • Overall rate is about 8 % – Bladder neck stenosis 1-3% – Urethral Stricture 1-2% – Secondary Haemorrhage 1.4% – Incontinence 1-3% – Retrograde Ejaculation 85 - 100% – Erectile Dysfunction 2 - 13 % – Mortality • 30 day post-op 0.3% • 90 day post-op 1.7% • Re-operation rate (within 5 years) 3-8%
  • 50. Transurethral radiofrequency needle ablation of the prostate (TUNA) • Low-level radiofrequency is transmitted to the prostate via a transurethral needle delivery system • The resultant heat causes localized necrosis of the prostate.
  • 51. Transurethral radiofrequency needle ablation of the prostate (TUNA) Side-effects • bleeding in 1/3 of patients • Short-term urinary retention in 10-40%. • UTI in 10% and urethral stricture in 2%. • Irritative urinary symptoms can last for a month or more. • No adverse effects on sexual function have been reported.
  • 52. Transurethral radiofrequency needle ablation of the prostate (TUNA) Efficacy • TUNA is a successful minimally invasive treatment option for symptoms associated with prostatic enlargement. • However, Concerns remain with regard to long-term effectiveness.
  • 53. Transurethral microwave thermotherapy (TUMT) • Microwave energy is delivered to the prostate via an intraurethral catheter which incorporates a microwave generator (antenna), a temperature measurement system, and a cooling system to prevent damage to the adjacent urethra.
  • 54. Transurethral microwave thermotherapy (TUMT) • The microwave energy produces prostatic heating and coagulative necrosis. • Subsequent shrinkage of the prostate and thermal damage to adrenergic neurons (i.e. heat-induced adrenergic nerve block) relieves obstruction • Cavities can be demonstrated 3 months post- treatment by TRUS. • Low-energy, high-energy, and high-intensity protocols are available.
  • 55. Transurethral microwave thermotherapy (TUMT) Side effects • Perineal discomfort is common after TUMT, as is urgency, but these symptoms usually resolve in a few days. • Sexual side-effects after TUMT (e.g. impotence, retrograde ejaculation) are less frequent that after TURP, • a catheter may be required for 1-2 week because of urinary retention in up to 25% of patients especially with higher-energy protocols.
  • 56. HIFU • A focused ultrasound beam can be used to induce a rise in temperature in the prostate, or indeed in any other tissue to which it is applied. • A transrectal probe is used for HIFU treatment of the prostate • There are no randomized trials comparing its effectiveness against other treatment modalities.
  • 57. TUVP • This technique vaporizes and dessicates the prostate. Advantages • TUVP is as effective as TURP for symptom control and relief of bladder outlet obstruction. • Requirement for blood transfusion may be slightly less after TUVP than after TURP. •
  • 58. TUVP Side effects • Retrograde ejaculation occurs 70-100% of patients and impotence in 0-15%. • Irritative symptoms seem to be more troublesome than after TURP and can last for 4-6 weeks. • TUVP does not provide tissue for histological examination, and so prostate cancers cannot be detected.
  • 59. LASER • Light • Amplification by the • Stimulated • Emission of • Radiation
  • 60. LASER • Penetration depends on wavelength. • Shorter wavelengths (600nm-700nm) are absorbed within a couple of mm by hemoglobin. • Longer wavelengths (1,000nm + ) are absorbed by fat and water.
  • 61. Laser Therapy Mechanism of action of Laser in prostatectomy: • Ablation (coagulation necrosis). • Resection. • Vaporization. These mechanisms are employed through 1) Visual laser ablation of the prostate. 2) Laser vaporization of the prostate. 3) Laser resection of the prostate. 4) Laser enucleation of the prostate (with tissue morcellation). 5) Laser incision of the prostate. 6) Interstitial laser coagulation of the prostate.
  • 63. Laser Therapy There are four types of laser for the prostate: 1) Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) laser: utilizes wavelengths of 1064 nm causing coagulative necrosis of the prostate. 2) Potassium Titanyl Phosphate (KTP) laser:  Doubling the frequency of pulsed (Nd:YAG) laser energy with a KTP crystal has led to the creation of a 532 nm wavelength selectively absorbed by Hb.  The 60-W KTP laser has proved that a higher-power laser beam could speed up vaporization.  So, the 80-W KTP laser was introduced (Green light photoselective vaporization laser system).
  • 64. Laser Therapy 3) Holmium: Yttrium-Aluminum-Garnet (Ho:YAG) laser: • The Ho:YAG utilises wavelength of 2140 nm. • It causes vaporization rather than coagulation. • can be used for resection (HoLRP) or enucleation (HoLEP). 4) Diode laser: has 3 components: 1. portable diode laser unit, 2. specialized fiber optic delivery system that allows optical monitoring of tissue temperatures, 3. laser.
  • 65. Visual laser ablation of the prostate It is based on the principle of laser coagulation. Surgical technique:  The laser energy is delivered to the prostate gland with a side-firing, noncontact, free-beam laser.  The most widely used laser energy is the Nd:YAG.  The obstructive tissue then starts to slough during the next 4 to 8 postoperative weeks, leading to a patent prostatic urethra. Adverse effects: Prolonged irritative voiding symptoms which may last for weeks and sometimes months.
  • 66. Laser vaporization of the prostate  The Green Light company improved the power of the 532 nm laser up to 80 W KTP and 120 W high-performance system (HPS) with lithium triborate (LBO).  Photoselective vaporization of the prostate (PVP) is considered an easy technique creating prostatic fossa resembling TURP. Indications of PVP: 1) Prostates larger than 80 ml can be done. 2) Patients with a high risk. 3) Elderly aged 80 years or more. 4) Anticoagulant users .
  • 67. Laser vaporization of the prostate Surgical technique:  Vaporization is started at the 6 o'clock position or at one of the two lateral lobes of the prostate.  Effective lasing makes many air bubbles.  A Foley catheter is placed for less than 24 hours before a voiding trial is done. Advantages No significant blood loss or fluid absorption was noted during or immediately after PVP. Side effects transient hematuria (8.6%), dysuria (9.3%) and urinary retention (5%).
  • 68. Laser resection of the prostate It is based on the principle of laser vaporization. Holmium: YAG is the most widely used laser for this technique. Surgical technique the laser fiber cuts the prostatic lobes into pieces small enough to be evacuated through the resectoscope sheath to create a TUR-like cavity.
  • 69. Laser enucleation of the prostate (with tissue morcellation) Indication: Alternative to open prostatectomy in large prostates. Surgical technique  Bilateral bladder neck incisions from orifices to veru.  The median lobe is enucleated then the lateral lobes.  Prostate tissues in the bladder are fragmented and aspirated with the morcellator. Adverse effects: Recatheterization (2.9%), UTI (2.3%), urethral stricture or bladder-neck contracture (3.2%) and reoperation (2.8%).
  • 70. Laser incision of the prostate • based on the principle of tissue vaporization • a contact-tip laser fiber is used to deliver high energy along the prostatic urethra, causing a linear tract of tissue vaporization. • It is performed on relatively small glands (< 30 g).
  • 71. INTERSTITIAL LASER COAGULATION  A standard cystoscope is used to insert the laser fiber transurethrally into the prostate gland.  The intraprostatic temperature reaches 100°C within a few seconds and is maintained for150 seconds resulting in tissue coagulation. Adverse Effects Retreatment rate in 16% and UTI in 20% of patients.
  • 72. Plasmakinetic vaporesection of the prostate (PKVP) A new technique based on creating a plasma arc, vaporizing tissue and achieving hemostasis to a predictable depth.
  • 73. Plasmakinetic vaporesection of the prostate (PKVP) • current is passed through the active electrode of the device that approaches boiling point and a plasma corona is formed, creating very high resistance between the active and return electrodes. • Tissue entering the corona (lower resistance) is vaporized and adjacent tissue is sealed up to 0.5 mm.
  • 74. Plasmakinetic vaporesection of the prostate (PKVP) Advantages of PKVP 1) The bipolar current and the use of saline irrigation eliminates the risk of TUR syndrome. 2) Hemostasis is achieved to a predictable depth. 3) The working element is the return electrode , thus, eliminating the risk of skin burns and obturator jerk. 4) Safe to be used in patients with cardiac pacemakers. 5) used in high risk patients, patients with bleeding disorder and patients receiving anticoagulative therapy. Disadvantages of PKVP It does not provide histopathological specimens which may miss incidental cancers.
  • 75. Trans-urethral resection in saline (TURis) • Using a bipolar electrode this technique allows working with saline medium. • The technique offers familial technique with minimal bleeding and use in high risk patients with cardiac pacemakers and arrhythmias.
  • 76. TURis and TUVis (PKVP) in motion